Adis celebrates 20 years of monitoring drugs in development

The AdisInsight team have recently celebrated a milestone for their drug pipeline database, R&D Insight, which published its first drug profile twenty years ago.

In 1994, the first drug profile was written by Stephanie Irvine, one of the founding members of the editorial team for a new database being launched by Adis. The profile was based on the drug Benidipine, a calcium antagonist developed by Kyowa Hakko for the treatment of essential hypertension and angina pectoris.

Since the profile was first created, the editorial team have continued to track the progress of the drug, building a twenty-year history of its development, including company agreements, pharmacodynamics data, and reports on adverse events and clinical trials. At present, Benidipine is marketed in Japan, Turkey, China and the Philippines (as Coniel®) and India (as Caritec®).

R&D Insight now contains profiles of over 30,000 drugs and covers drug- and cell-based products worldwide, focusing on those in development by industry, or with industry involvement, where the drug will be regulated as a prescription drug or available only to physicians for administration.

Glenn Whiteside, Product Specialist for R&D Insight at Adis remarks

“Our goal has always been to provide our users with the most relevant, scientifically-sound data on drugs in development, and we are really proud of the product that we have built over the last two decades”.

The database has thousands of users globally from pharmaceutical companies to universities, hospitals to financial institutions. To support their wide range of users, Adis is in the process of developing a new platform for its AdisInsight database content, which is due to be launched in 2015.

Mike Sumner, VP for Adis Product Management & Development at Springer, states

“This is a really exciting time for AdisInsight as we work on a new platform that will bring together all of our content on drugs, trials, deals and safety for the first time. I believe that the new AdisInsight will help our users to carry out their research faster, make greater discoveries and really benefit from the scientific expertise behind each record.”

The full profile for Benidipine can be viewed here. For more information about R&D Insight, please visit

Adis involved in the First EMR/Arab Countries meeting

Adis was pleased to be involved in a breakthrough pharmacovigilance event hosted by the Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM), which took place on 22-26 September 2014 in Rabat, the capital city of Morocco.

The summit was organized by CAPM in association with the Moroccan Society of Pharmacovigilance (SMPV), the Council for International Organizations of Medical Sciences (CIOMS), the International Society of Pharmacovigilance (ISoP) and Springer.

The purpose of the meeting was to promote interaction, exchange information, implement and reinforce national pharmacovigilance activities in Arabic countries and define an action plan for its development.

Attendees of the meeting

Springer offers a range of products and services in drug safety and pharmacovigilance through the Adis brand, and got involved in the event with a view to understanding the needs of Arab countries when it comes to monitoring the safety of medicines, as well as possibly providing support and resources that may help with building awareness and respond to work and educational needs.

Daniela Ranzani, Product Manager for Pharmacovigilance at Adis, hosted a presentation on the challenges and trends in literature monitoring for pharmacovigilance and stated

“The content presented at this meeting was extremely valuable, as were the working groups that were established for discussion of topics such as integrated pharmacovigilance systems, harmonization of terminology and definitions, risk minimization plans and how to strengthen national pharmacovigilance systems for vaccines. We firmly believe that this was the first milestone in a series of events, whether they are discussion forums or educational workshops, and Springer is ready to engage further with this vital segment , to collaborate with centers in this region, and to provide them with any support and resources they may need.”

The meeting was also attended by Nadja Madani, Springer’s Licensing Manager for Health, Hospitals & Pharma in the region, who commented:

“We were very pleased to participate in the meeting, which had a rich programme including presentations and participation from several regional and international authorities, including the WHO, the US FDA, the Arab League, the Uppsala Monitoring Centre, experts from the Industry, representatives from national drug safety authorities and Health Ministries in the Arab region, amongst others. A special thanks goes to Rachida Soulaymani, Head of the Centre Anti Poison et de Pharmacovigilance du Maroc, for having us and to all of her wonderful staff and participants – we hope to see them all again soon.”

A full meeting report will be published soon in one of the Adis Journals.